Stronger partnerships between research institutions, government, academia, private industry, and community-based philanthropies, along with innovative, adaptable, standardized, and scalable MCM development technologies can facilitate rapid development of new MCMs to combat emerging threats. Meeting demand during an emergency requires fast production of products with quality control standards to ensure access to safe MCMs. Furthermore, producing and distributing MCMs that meet the needs of at-risk individuals and underserved communities is essential to health security.
- Flexible partnerships and adaptable research, development, and approval processes are in place to conduct research to develop new and repurposed MCMs in an emergency, to assess them for safety and efficacy through clinical trials, to ensure standardization and scale-up of manufacturing, and to determine when and whether they should be authorized for use in the general population.
- MCM development and distribution of authorized MCMs is maximized to meet the diverse needs of all segments of the population.
Federal Implementation Actions:
3.3.1 Engage with industry and subject matter experts to identify cutting-edge technologies and opportunities to innovate MCM development, assessment, and regulatory practices.
3.3.2 Examine proven technologies and established partnerships to develop processes that can rapidly standardize and scale up MCM production and equitable distribution during a response.
3.3.3 Expand partnerships and innovation programs for research and development of diagnostics, antimicrobial drugs, therapeutics, and preventative products to combat rising antimicrobial resistance and other neglected threats.
3.3.4 Pursue MCM design and clinical trial approaches that consider diversity, equity, and inclusion to represent the needs of all population segments.